News

Zydus receives approval from Health Canada for Mesalamine suppositories

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis

Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for generic Mesalamine suppositories 1000 mg.

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.

ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Ltd. Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

Upcoming E-conference

Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

July 17, 2026

Register Now

Other Related stories

FDA advisory panel backs Moderna flu vaccine candidate for older adults

FDA clears 131 drugs as global pharma approval momentum rebounds in 2025

Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results

Interviews

India is b

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India

Cancer tre

Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics

We plan to

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Appointments

Pfizer CFO Dave Denton to exit

Pfizer CFO Dave Denton to exit

Saurabh Gambhir elevated to Chief Strategy Officer (Global) at Cipla

Saurabh Gambhir elevated to Chief Strategy Officer (Global) at Cipla

Dr. Dhananjay Kumar Tiwary gets additional charge as Managing Director of BIRAC

Dr. Dhananjay Kumar Tiwary gets additional charge as Managing Director of BIRAC

Startup

Lumos Health opens applications for second cohort of HealthTech and MedTech startups

Lumos Health opens applications for second cohort of HealthTech and MedTech startups

Hoola Health raises $5 million to expand child-centric paediatric care

Hoola Health raises $5 million to expand child-centric paediatric care

HealthFab raises Rs 20 crore in Series A funding from Atomic Capital

HealthFab raises Rs 20 crore in Series A funding from Atomic Capital

Digitization

CENT expands to Delhi-NCR with new clinical prevention centre in Gurugram

CENT expands to Delhi-NCR with new clinical prevention centre in Gurugram

proRITHM named among top 4 AI-based healthcare technologies

proRITHM named among top 4 AI-based healthcare technologies

Life sciences firms move from AI pilots to scaled adoption, finds KPMG Global Tech Report 2026

Life sciences firms move from AI pilots to scaled adoption, finds KPMG Global Tech Report 2026

Upcoming E-conference

July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

Teva submits FDA application for experimental Tourette syndrome treatment ecopipam

FDA advisory panel backs Moderna flu vaccine candidate for older adults

FDA clears 131 drugs as global pharma approval momentum rebounds in 2025

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Opinion

NCAHP Act has built backbone of India’s healthcare workforce: Nalin Saluja, Co-Founder & CTO, Virohan

NCAHP Act has built backbone of India’s healthcare workforce: Nalin Saluja, Co-Founder & CTO, Virohan

Insect biotech as India's next deeptech opportunity: Ankit Alok Bagaria, Co-founder and CEO, Loopworm

Insect biotech as India's next deeptech opportunity: Ankit Alok Bagaria, Co-founder and CEO, Loopworm

Interviews

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India

Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International

Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics

Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics

Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging

Clariant boosts high-speed packaging efficiency with expanded continuous strip desiccant reels

Clariant boosts high-speed packaging efficiency with expanded continuous strip desiccant reels

Coveris invests €1.8m in Poland to boost speed, capacity & packaging innovation

Coveris invests €1.8m in Poland to boost speed, capacity & packaging innovation

Northamptonshire NHS Trust ditches disposable cups in bold sustainability move

Northamptonshire NHS Trust ditches disposable cups in bold sustainability move